M. Walraven

A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer

T. D. de Gruijl, A. Griffioen, H. Verheul, 2016, British Journal of Cancer.

Targeting the Endothelin Axis with Atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma

G. Groenewegen, E. Voest, J. Haanen, 2012, British Journal of Cancer.

Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry.

E. Giovannetti, C. Tibaldi, E. Smit, 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Blood platelets contain tumor-derived RNA biomarkers.

T. Wurdinger, W. Vandertop, H. Verheul, 2011, Blood.

Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.

M. Lubberink, A. Lammertsma, A. Windhorst, 2012, Cancer cell.

Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab

E. Voest, H. Verheul, M. Roest, 2018, Angiogenesis.

Effects of Cancer Presence and Therapy on the Platelet Proteome

M. O. oude Egbrink, A. Griffioen, H. Verheul, 2021, International journal of molecular sciences.

Symptoms from treatment with sunitinib or sorafenib: a multicenter explorative cohort study to explore the influence of patient-reported outcomes on therapy decisions

H. Verheul, P. Witteveen, R. Vos, 2014, Supportive Care in Cancer.

Pazopanib-related tumor lysis syndrome in metastatic clear cell renal cell carcinoma: a case report

M. Hendriks, M. Walraven, M. W. V. Kalleveen, 2018, Investigational New Drugs.

Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review

R. van Hillegersberg, E. Voest, H. Verheul, 2010, Angiogenesis.

Effects of the antiangiogenic drug bevacizumab on tumor perfusion and drug delivery of 11C-labeled docetaxel in patients with non-small cell lung cancer (NSCLC): Implications for scheduling of antiangiogenic agents.

M. Lubberink, A. Lammertsma, A. Windhorst, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.